Research Nester released a report titled “Erythropoietin Stimulating Agents Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global erythropoietin stimulating agents market in terms of market segmentation by agent, by application and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Erythropoiesis is the process of synthesis of red blood cells through stimulation of the bone marrow. Erythropoietin stimulating agents (ESAs) are chemical substances used as drugs in order to product more blood cells in the body. They are majorly used in cases of anemia caused by various disorders in patients. The market for erythropoietin stimulating agents is projected to grow at a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by agent, by application and by region. On the basis of application, the market is sub-segmented into cancer, neural disorders, kidney disorders, anemia and others. The segment for kidney disorders is estimated to hold the largest share in the market. This can be attributed to the growing number of chronic kidney disease among people across the world. Further, the cancer segment is anticipated to hold a noteworthy share in this market on account of rising usage of ESAs among patients undergoing cancer therapy such as chemotherapy. According to the World Bank, the prevalence of anemia among women between 15 and 49 years, i.e., of the reproductive age, is 32.8% in the world. Cancer-associated anemia interferes with cancer therapies which increases the demand for these agents.
On the basis of region, the erythropoietin stimulating agents market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The growing medical tourism along with an incline in the purchasing power of people, the market in Asia Pacific is estimated to expand at the highest rate over the forecast period. On the other hand, the market in North America is predicted to hold the largest share in the market as a result of high prevalence of disorders that lead to anemia among patients in the region.
Growing Number of Approved Biosimilar Drugs to Propel the Market Growth
Development and production of various new forms of erythropoietin stimulating agents by pharmaceutical manufacturers results in growing commercialization of these drugs and reduction in their prices. This is anticipated to boost the market growth substantially. However, the side effects associated with EPAs, including nausea, fever, swelling and others is estimated to restrict the market growth in the upcoming years.
This report also provides the existing competitive scenario of some of the key players of the global erythropoietin stimulating agents market which includes company profiling of Amgen Inc. (NASDAQ: AMGN), Pfizer, Inc. (NYSE: PFE), F. Hoffmann-La Roche Ltd. (SWX: ROG), Johnson & Johnson Services, Inc. (NYSE: JNJ), Thermo Fisher Scientific (NYSE:TMO), Fuji Pharma (TYO: 4554), Cigna (NYSE: CI), Sandoz International GmbH, Biocon (NSE: BIOCON) and 3SBio Group (HKG: 1530). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global erythropoietin stimulating agents market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.